Loading...

IMUX IMMUNIC INC Product Launches 8-K Filing

MMNC

MX

IMMUNIC INC

(IMUX)

2025 8-K

Financial Results Update

Data Presentation Update

Financial Statements

Notice of Delisting

Rights Offerings

Equity Offerings

Equity Offerings

Clinical Trial Update

CEO Employment Agreement

Financial Results

Positive Trial Results

R&D Day Summary

Management Change

Financial Results Announcement

Appointment of Director

Appointment of COO and Pres...

Annual Meeting of Stockholders

Earnings Reports

Amendment to Increase Autho...

Financial Results and Corpo...

Private Placement

Management Agreements

Financial Results Announcement

Extension of Employment Ter...

Positive Interim Data from ...

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Report

Clinical Trial Results

Appointments, Retirement

Press Release and Presentation

Liquidity Concern at Silico...

Financial Results Announcement

Press Release and Presentation

Management Agreements

External Links:

On September 25, 2025, Immunic, Inc. announced the presentation of key data on vidofludimus calcium at the ECTRIMS conference. The company released new findings from the Phase 2 CALLIPER trial on September 24, 2025.

AI Assistant

IMMUNIC INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.